A BuiltForAI Property
Live federal data · NADAC weekly · Part D CY24

Flurbiprofen Etodolac

Flurbiprofen vs Etodolac — $17.8M of combined CY2024 Part D plan spend across 2 molecules. Side-by-side data, every number traced to its CMS or FDA source.

Last updated
NADAC: refreshed weeklyPart D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily

Pick the drugs you want to compare.

Up to 4 drugsCross-class or same-class

Start with the molecules your plan spends the most on. Most useful comparisons live within the same therapeutic class — switching across classes requires deeper clinical review.

Drug 1
Drug 2
Drug 3 (optional)
Drug 4 (optional)

Side by side, line by line.

Federal data onlyNo PBM pricing assumed
Compare across
11 dimensions
Nonsteroidal Anti-inflammatory Drug
Flurbiprofen
Brand: LURBIRO
First FDA approval:
Nonsteroidal Anti-inflammatory Drug
Etodolac
First FDA approval:
Lowest NADACAcquisition cost floor across all NDCs
$3.23Per unit
$0.253Per unit
Average NADACAcross all dosage forms and strengths
$5.55Up to $10.18
$0.660Up to $1.07
Generic manufacturersActive ANDA holders — FDA Orange Book
22 total ANDAs filed
1134 total ANDAs filed
Annualized Part D spendCY2024 — CMS Part D Spending Dashboard
$2.0MFull year
$15.9MFull year
Part D claims (CY24)Total fills, all strengths
47K24K beneficiaries
391K170K beneficiaries
Avg cost per claimCalculated: total spend ÷ total claims
$42Per claim, all NDCs
$41Per claim, all NDCs
Part D plans surveyed2026 plan year — CMS Formulary file
329Across CMS plan year
329Across CMS plan year
Prior-authorization frictionPlan-NDC pairs requiring PA
0Zero PA friction
0Zero PA friction
Step therapy appliedPlan-NDC pairs requiring step therapy
0None
0None
FDA shortage statusLive cross-reference vs FDA Drug Shortage Database
NoneClear
NoneClear
Generic availableFDA Orange Book
Yes2 manufacturers
Yes11 manufacturers